Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.

Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C.

Vaccine. 2017 Dec 19;35(52):7283-7291. doi: 10.1016/j.vaccine.2017.11.006. Epub 2017 Nov 14.

2.

Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial.

Kanungo S, Kim DR, Haldar B, Snider C, Nalavade U, Kim SA, Park JY, Sinha A, Mallick AH, Manna B, Sur D, Nandy RK, Deshpande JM, Czerkinsky C, Wierzba TF, Petri WA Jr, Ali M, Dey A.

Heliyon. 2017 Jan 9;3(1):e00223. doi: 10.1016/j.heliyon.2016.e00223. eCollection 2017 Jan.

3.

The Duration of Intestinal Immunity After an Inactivated Poliovirus Vaccine Booster Dose in Children Immunized With Oral Vaccine: A Randomized Controlled Trial.

John J, Giri S, Karthikeyan AS, Lata D, Jeyapaul S, Rajan AK, Kumar N, Dhanapal P, Venkatesan J, Mani M, Hanusha J, Raman U, Moses PD, Abraham A, Bahl S, Bandyopadhyay AS, Ahmad M, Grassly NC, Kang G.

J Infect Dis. 2017 Feb 15;215(4):529-536. doi: 10.1093/infdis/jiw595.

4.

Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M.

J Infect Dis. 2017 Feb 1;215(3):335-343. doi: 10.1093/infdis/jiw542.

5.

Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.

Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, Rüttimann R, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Dec;16(12):1377-1384. doi: 10.1016/S1473-3099(16)30169-4. Epub 2016 Sep 13.

6.

Peyer's patches: organizing B-cell responses at the intestinal frontier.

Reboldi A, Cyster JG.

Immunol Rev. 2016 May;271(1):230-45. doi: 10.1111/imr.12400. Review.

7.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C.

PLoS One. 2016 Jan 5;11(1):e0146010. doi: 10.1371/journal.pone.0146010. eCollection 2016.

8.

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Parker EP, Molodecky NA, Pons-Salort M, O'Reilly KM, Grassly NC.

Expert Rev Vaccines. 2015;14(8):1113-23. doi: 10.1586/14760584.2015.1052800. Epub 2015 Jul 9. Review.

9.

Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.

Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK.

Lancet Infect Dis. 2015 Aug;15(8):889-97. doi: 10.1016/S1473-3099(15)00093-6. Epub 2015 Jun 17.

10.

The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems.

Kirkpatrick BD, Colgate ER, Mychaleckyj JC, Haque R, Dickson DM, Carmolli MP, Nayak U, Taniuchi M, Naylor C, Qadri F, Ma JZ, Alam M, Walsh MC, Diehl SA; PROVIDE Study Teams, Petri WA Jr.

Am J Trop Med Hyg. 2015 Apr;92(4):744-51. doi: 10.4269/ajtmh.14-0518. Epub 2015 Feb 23.

11.
12.

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Dietrich J, Andreasen LV, Andersen P, Agger EM.

PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879. eCollection 2014.

13.

Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine.

Herrera D, Vásquez C, Corthésy B, Franco MA, Angel J.

Hum Vaccin Immunother. 2013 Nov;9(11):2409-17. Epub 2013 Jul 9.

14.

The final stages of the global eradication of poliomyelitis.

Grassly NC.

Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120140. doi: 10.1098/rstb.2012.0140. Print 2013 Aug 5. Review.

15.

Successes and shortcomings of polio eradication: a transmission modeling analysis.

Mayer BT, Eisenberg JN, Henry CJ, Gomes MG, Ionides EL, Koopman JS.

Am J Epidemiol. 2013 Jun 1;177(11):1236-45. doi: 10.1093/aje/kws378. Epub 2013 Apr 16.

17.

Seroepidemiology of polioviruses among university students in northern Italy.

Baldo V, Baldovin T, Cocchio S, Lazzari R, Saracino E, Bertoncello C, Buja A, Trevisan A.

Clin Vaccine Immunol. 2012 Aug;19(8):1292-5. doi: 10.1128/CVI.00054-12. Epub 2012 Jun 27.

18.

Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge.

Hird TR, Grassly NC.

PLoS Pathog. 2012;8(4):e1002599. doi: 10.1371/journal.ppat.1002599. Epub 2012 Apr 19. Review.

19.

Persistence of diarrheal pathogens is associated with continued recruitment of plasmablasts in the circulation.

Kantele A.

Clin Dev Immunol. 2012;2012:279206. doi: 10.1155/2012/279206. Epub 2012 Jan 19.

20.

Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Carmichael JR, Pal S, Tifrea D, de la Maza LM.

Vaccine. 2011 Jul 18;29(32):5276-83. doi: 10.1016/j.vaccine.2011.05.013. Epub 2011 May 24.

Supplemental Content

Support Center